术前短程放疗序贯FOLFOX新辅助治疗对比长程放化疗改善直肠癌无转移生存与无病生存:配对分析结果
一项配对分析比较了局部晚期直肠癌患者接受近全量新辅助治疗(nTNT,术前短程放疗序贯FOLFOX)与标准新辅助放化疗(NCRT)的疗效。nTNT组3年无病生存率显著优于NCRT组(85% vs 68%,P=.032),T降期率更高(75% vs 41%,P<.001),且多因素分析显示nTNT与更低复发风险显著相关(P=.006)。
要点
- nTNT组3年无病生存率显著高于NCRT组(85% vs 68%,P=.032)。
- nTNT组T降期率显著更高(75% vs 41%,P<.001),pCR率两组差异无统计学意义(28% vs 16%,P=.21)。
- 多因素分析显示nTNT与更低复发风险独立相关(P=.006)。
核心结论
- nTNT组T降期率更高,无远处转移生存和无病生存优于常规NCRT,且在多因素分析中nTNT仍与更低复发风险显著相关。
研究设计与样本
- 第二分析纳入斯坦福大学41例接受NCRT的患者。
- 采用Kaplan-Meier法和log-rank检验比较局部控制、无远处转移生存、无病生存和总生存。
主要发现
- nTNT组与NCRT组中位随访分别为49个月和54个月。
- nTNT组与NCRT组病理完全缓解率分别为28%和16%(P=.21),T降期率分别为75%和41%(P<.001)。
- nTNT组3年无病生存率显著优于NCRT组(85% vs 68%,P=.032)。
- 两组3年局部控制率(92% vs 96%,P=.36)和总生存率(96% vs 88%,P=.67)相似。
- 控制临床分期、年龄、肿瘤位置、机构和化疗周期数后,nTNT仍与更低复发风险显著相关(P=.006)。
临床怎么用
- 对于局部晚期直肠癌,术前短程放疗序贯FOLFOX的nTNT策略可能改善无病生存和远处转移控制,但需在合适患者中权衡。
局限性
- nTNT为单臂二期试验,对照为历史队列,样本量有限,结论需前瞻性随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare treatment and toxicity outcomes between a phase 2 institutional trial of near total neoadjuvant therapy (nTNT) for locally advanced rectal cancer and a similar historical control cohort treated at Washington University in St. Louis with the current US standard of care, defined as neoadjuvant chemoradiotherapy (NCRT), total mesorectal excision (TME), and adjuvant FOLFOX chemotherapy; to expand the comparison to an additional institution, patients treated with similar NCRT at Stanford University were included. METHODS AND MATERIALS: Sixty-nine patients with cT3-4N0-2M0 rectal adenocarcinoma enrolled on the Washington University in St. Louis phase 2 study of nTNT were included for analysis. Patients treated at the same institution with conventional NCRT and adjuvant FOLFOX were matched for exact cTNM stage. Forty-one patients treated with NCRT at Stanford University were included in a second analysis. Kaplan-Meier analysis with log-rank test was used to compare local control, distant metastasis-free survival, disease-free survival, and overall survival. RESULTS: Median follow-up was 49 and 54 months for nTNT and NCRT, respectively. Pathologic complete response and T-downstaging rates were 28% versus 16% (P=.21) and 75% versus 41% (P<.001) in the nTNT and NCRT cohorts, respectively. Three-year disease-free survival (85% vs 68%, P=.032) was significantly better in the nTNT group. Actuarial 3-year local control (92% vs 96%, P=.36) and overall survival (96% vs 88%, P=.67) were similar. The Stanford cohort had significantly lower clinical stage. After controlling for clinical stage, age, tumor location, institution, and number of chemotherapy cycles, nTNT treatment remained significantly associated with lower risk of recurrence (P=.006). CONCLUSIONS: Patients treated with nTNT had higher T-downstaging and superior distant metastasis-free survival and disease-free survival compared with conventional NCRT when matched for tumor location and exact cTNM stage. Near total neoadjuvant therapy remained a significant multivariate predictor for improved outcome when including patients treated with NCRT at another institution.
引用
- Markovina S, Youssef F, Roy A, et al. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 28871992. doi:10.1016/j.ijrobp.2017.05.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。